Fampridine-SR in multiple sclerosis: a randomized,double-blind,placebo-controlled,dose-ranging study

Abstract

Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily.

Method Multicenter, randomized, double-blind, placebo-controlled, study. Following a 4-week baseline peroid, subjects were randomly assigned to receive Fampridine-SR (n=25, doses from 10 to 40 mg twice daily, increasing in 5 mg increments weekly) or placebo (n=11). A battery of assessments was performed weekly, including the MS Functional Composite (MSFC), fatigue questionnaires, and lower extremity manual muscle testing.

Results The most common adverse events were dizziness, insomnia, paresthesia, asthenia, nausea, headache, and tremor. Five subjects were discontinued from Fampridine-SR because of adverse events at doses greater than 25 mg, and these included convulsions in two subjects at doses of 30 and 35 mg twice daily. Improvement were seen in lower extremity muscle strength (prospective analysis) and walking speed (post-hoc analysis) in the Fampridine-SR group compared to placebo (unadjusted p-values of 0.01 and 0.03, respectively). There were no significant differences in other MSFC measure or fatigue scores.

Conclusions Future studies should employ doses up to 20 mg twice daily with lower extremity strength and walking speed as potential outcome measures. Multiple Sclerosis 2007; 13: 357-368. http://msj.sagepub.com

Keywords

4-aminopyridine clinical trial Fampridine-SR multiple sclerosis safety

Get full access to this article

View all access options for this article.

References

Hayes KC , Potter PJ , Hsieh JT , Katz MA , Blight AR , Cohen R. Pharmacokinetics and saflety ofl multiple oral doses ofl sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury . Arch Phys Med Rehabil 2004; 85: 29-34 .

Targ EF , Kocsis JD 4- Aminopyridine leads to restoration ofl conduction in demyelinated rat sciatic nerve . Brain Res 1985; 328: 358-61 .

Blight AR Eflflect ofl 4-aminopyridine on axonal conduction-block in chronic spinal cord injury . Brain Res Bull 1989; 22: 47-52 .

Blight AR , Toombs JP , Bauer MS , Widmer WR The eflflects ofl 4-aminopyridine on neurological deficits in chronic cases ofl traumatic spinal cord injury in dogs: a phase I clinical trial . J Neurotrauma 1991; 8: 103-19 . 5. Waxman SG Aminopyridines and the treatment ofl spinal cord injury . J Neurotrauma 1993; 10: 19-24 .

Stefoski D. , Davis FA , Faut M. , Schauf CL 4- Aminopyridine improves clinical signs in multiple sclerosis . Ann Neurol 1987; 21: 71-77 .

Stefoski D. , Davis FA , Fitzsimmons WE , Luskin SS , Rush J. , Parkhurst GW 4- Aminopyridine in multiple sclerosis: prolonged administration . Neurology 1991; 41: 1344-48 .

Bever CT Jr, Young D. , Anderson PA , Panitch HS , Dhib-Jalbut S. , Khan OA et al. The eflflects ofl 4aminopyridine in multiple sclerosis patients: results ofl a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial . Neurology 1994; 44: 1054-59 .

Schwid SR , Petrie MD , McDermott MP , Tierney DS , Mason DH , Goodman AD Quantitative assessment ofl sustained-release 4-aminopyridine flor symptomatic treatment ofl multiple sclerosis . Neurology 1997; 48: 817-21 .

van Diemen Ham , Polman CH , van Dongen Tmmm , van Loenen AC , Nauta Jjp , Taphoorn Mjb et al. The eflflect ofl 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study . Ann Neurol 1992; 32: 123-30 .

10.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS) . Neurology 1983; 33: 1444-52 .

11.

Sanders DB , Kim YI , Howard JF Jr , Goetsch CA Eaton-Lambert syndrome: a clinical and electrophysiological study ofl a patient treated with 4-aminopyridine . J Neurol Neurosurg Psychiatry 1980; 43: 978-85 .

12.

Jones RE , Heron JR , Foster DH , Snelgar RS , Mason. Eflflects ofl 4-aminopyridine in patients with multiple sclerosis . J Neurol Sci 1983; 60: 353-62 .

13.

Davis FA , Stefoski D. , Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis . Ann Neurol 1990; 27: 186-92 .

14.

Lundh H. , Nilsson O. , Rosén I. Eflflects ofl 4-aminopyridine in myasthenia gravis . J Neurol Neurosurg Psychiatry 1979; 42: 171-75 .

15.

Ball AP , Hopkinson RB , Farrell ID , Hutchison JG , Paul R. , Watson RD et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak . Q J Med 1979; 48: 473- 91 .

16.

Murray NM , Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders ofl neuromuscular transmission . Neurology 1981; 31: 265-71 .

17.

Spyker DA , Lynch C. , Shabanowitz J. , Sinn JA Poisoning with 4-aminopyridine: report ofl three cases . Clin Toxicol 1980; 16: 487- 97 .

18.

van Diemen HAM , Polman CH , Koetsier JC , van Loenen AC , Nauta JJP , Bertelsmann. 4- Aminopyridine in patients with multiple sclerosis: dosage and serum level related to eflficacy and saflety . Clin Neuropharmacol 1993 ; 16: 195- 204 .

19.

Schwid SR , Goodman AD , Mattson DH , Minai C. , Donohoe KM , Petrie MD et al. The measurement ofl ambulatory impairment in multiple sclerosis . Neurology 1997; 49: 1419-24 .

20.

Balcer LJ Clinical outcome measures flor research in multiple sclerosis . J Neuroophthalmol 2001; 21: 296-301 . 22. Poser CM , Paty DW , Scheinberg L. , McDonald WI , Davies FA , Ebers GC et al. New diagnostic criteria flor multiple sclerosis: guidelines flor research protocols . Ann Neurol 1983; 13: 227-31 .

21.

Krupp LB , LaRocca NG , Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus . Arch Neurol 1989; 46: 1121-23 .

22.

Mendoza TR , Wang XS , Cleeland CS , Morrissey M. , Johnson BA , Wendt JK et al. The rapid assessment ofl flatigue severity in cancer patients . Cancer 1999; 85: 1186-96 .

23.

Fischer JS , LaRocca NG , Miller DM , Ritvo PG , Andrews H. , Paty D. Recent developments in the assessment ofl quality ofl lifle in multiple sclerosis (MS) . Mult Scler 1999; 5: 251-59 .

24.

Cutter GR , Baier ML , Rudick RA , Cookfair DL , Fischer JS , Petkau J. et al. Development ofl a multiple sclerosis flunctional composite as a clinical trial outcome measure . Brain 1999 ; 122: 871-82 .

25.

Fischer JS , Jak AJ , Kniker JE , Rudick RA , Cutter G. Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual. Retrieved 30 March 2005, flrom http://www.nationalmssociety.org/%5CMUCS_MSFC.asp

26.

Schwid SR , Thornton CA , Pandya S. , Manzur KL , Sanjak K. , Petrie MD et al. Quantitative assessment ofl motor flatigue and strength in multiple sclerosis . Neurology 1999; 53: 743-50 .

27.

Ghezzi A. , Montanini R. , Basso PF , Zaffaroni M. , Massimo E. , Cazzullo CL Epilepsy in multiple sclerosis . Eur Neurol 1990; 30: 218-23 .